Drug intelligence / Profile preview

Fiebre Aftosa Vaccine

Development stage: Preclinical
Lead developer: VaxThera
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics

Overview

Fiebre Aftosa Vaccine is a veterinary viral vector vaccine being developed by VaxThera, a Colombian biotechnology company. The vaccine is designed to provide protective immunity against Foot and Mouth Disease (FMD), also known as Fiebre Aftosa, which is a highly infectious viral disease affecting cloven-hoofed animals such as cattle, pigs, and sheep. Utilizing a viral vector platform, the vaccine aims to deliver specific antigens to the host's cells to trigger an immune response without the use of the live virus. The project is currently in the preclinical stage of development and represents part of VaxThera's expansion into the veterinary health market.

Other names: Foot and Mouth Disease VaccineVacuna contra la Fiebre Aftosa

Beyond the preview

Go deeper on Fiebre Aftosa Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fiebre Aftosa Vaccine.

Explore the full profile